CVRx, Inc. (CVRX)

Over the past six months, CVRx's stock price has increased by 47.35%, despite a 33.09% decrease over the past year. In Q2 2025, CVRx reported a 15% year-over-year revenue increase to $13.6 million and narrowed its full-year revenue guidance to $55 million-$57 million. In Q3 2025, revenue reached $14.7 million, a 10% year-over-year growth, exceeding analyst estimates, and EPS showed a loss of $0.49, slightly better than anticipated, leading to increased price targets from Cantor Fitzgerald and Canaccord Genuity. The CMS finalized its 2026 payment rule, ensuring payment stability for CVRx's Barostim procedure. Johnson & Johnson Innovation - JJDC, Inc. sold 2,700 shares of common stock for $27,132 in late November 2025. CVRx's Q1 2025 revenue of $12.3 million, a 15% increase year-over-year, fell short of internal expectations due to sales force realignment and seasonality, causing a 40% drop in the stock price.

CVRx experiences some demand seasonality, with a typical dip in the first quarter due to patients delaying procedures. Due to the company's limited operating history and expected future expansion, its seasonal patterns have been difficult to discern and predict. Management is confident that this seasonal softness is temporary, and the company is focused on building a strong sales force and expanding its market presence to mitigate the impact of seasonality.

CVRx, Inc. is a commercial-stage medical device company specializing in neuromodulation solutions for cardiovascular diseases. Its flagship product, the Barostim Neo™ System, is an FDA-approved implantable device for treating heart failure and resistant hypertension by regulating cardiovascular function through the baroreflex mechanism. CVRx sells its products through a direct sales force, sales agents, and independent distributors.

CVRx, Inc. operates in the United States, Germany, and other international countries, with a significant market presence in the U.S. and Europe. As of June 30, 2025, CVRx had 240 active implanting centers in the U.S., up from 227 in March 2025, reflecting a 19% increase since March 31, 2024.

CVRx maintains a strong emphasis on integrity and compliance within the regulated medical device industry, adhering to FDA standards. Its mission focuses on developing innovative cardiovascular therapies and improving patient outcomes through neuromodulation technologies. The FDA approval of the Barostim Neo™ System and its Breakthrough Device designation enhance its reputation as a pioneer in cardiovascular neuromodulation. No negative events affecting CVRx's brand reputation have been reported in the past year.

CVRx, Inc. is primarily owned by institutional shareholders (53.43%) and company insiders (81.77%), with retail investors holding 0.00% of the stock. Johnson & Johnson Innovation - JJDC, Inc. is the largest individual shareholder, owning 7.55 million shares, representing 28.79% of the company. Other major owners include NEA Management Company, LLC, Vanguard Group Inc., Blackrock, Inc., and Balyasny Asset Management L.P.